ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Pacific Biosciences of California Inc

Pacific Biosciences of California Inc (PACB)

1.875
0.005
(0.27%)
Closed May 29 4:00PM
1.84
-0.035
(-1.87%)
After Hours: 7:30PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.84
Bid
1.83
Ask
1.89
Volume
5,698,585
1.81 Day's Range 1.95
1.25 52 Week Range 14.55
Market Cap
Previous Close
1.87
Open
1.88
Last Trade
8
@
1.88
Last Trade Time
Financial Volume
$ 10,574,947
VWAP
1.8557
Average Volume (3m)
11,184,121
Shares Outstanding
267,951,880
Dividend Yield
-
PE Ratio
-1.63
Earnings Per Share (EPS)
-1.14
Revenue
200.52M
Net Profit
-306.74M

About Pacific Biosciences of California Inc

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide ra... Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe. Show more

Sector
Lab Analytical Instruments
Industry
Lab Analytical Instruments
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Pacific Biosciences of California Inc is listed in the Lab Analytical Instruments sector of the NASDAQ with ticker PACB. The last closing price for Pacific Biosciences of C... was $1.87. Over the last year, Pacific Biosciences of C... shares have traded in a share price range of $ 1.25 to $ 14.55.

Pacific Biosciences of C... currently has 267,951,880 shares outstanding. The market capitalization of Pacific Biosciences of C... is $501.07 million. Pacific Biosciences of C... has a price to earnings ratio (PE ratio) of -1.63.

PACB Latest News

Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases

Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases PR Newswire ALISO VIEJO, Calif. and MENLO...

PacBio Announces First Quarter 2024 Financial Results

PacBio Announces First Quarter 2024 Financial Results PR Newswire MENLO PARK, Calif., May 9, 2024 MENLO PARK, Calif., May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial...

PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance

PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance PR Newswire MENLO PARK, Calif., April 16, 2024 Announces Plan to Reduce Annualized Operating Expense Run...

Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes PR Newswire MENLO PARK, Calif., March 27, 2024 HiFi Data Generated on the Revio™ System will Support the EU and Estonian...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.09-4.663212435231.932.031.7795036511.88795484CS
40.158.875739644971.692.671.565121255841.92843037CS
12-2.98-61.82572614114.825.011.25111841212.45732296CS
26-6.65-78.32744405188.4910.651.2592713204.55219828CS
52-10.85-85.50039401112.6914.551.2567209626.28987912CS
156-25.46-93.260073260127.336.361.2553149968.91978164CS
260-4.94-72.86135693226.7853.691.25427056710.99256462CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.08M
AWINAERWINS Technologies Inc
$ 8.99
(139.10%)
5.41M
INSMInsmed Inc
$ 48.107
(118.67%)
33.42M
GVVisionary Holdings Inc
$ 0.38
(90.00%)
10.33M
SOBRSOBR Safe Inc
$ 0.41
(82.22%)
130.83M
APDNApplied DNA Sciences Inc
$ 0.580601
(-70.82%)
9.46M
LUCYInnovative Eyewear Inc
$ 0.40
(-59.31%)
85M
MRAIMarpai Inc
$ 0.90
(-53.61%)
803.83k
TOIIWOncology Institute Inc
$ 0.021
(-52.60%)
293.22k
SHOTWSafety Shot Inc
$ 0.21
(-36.07%)
24.26k
PEGYPineapple Energy Inc
$ 0.2595
(45.70%)
676.68M
GWAVGreenwave Technology Solutions Inc
$ 0.0782
(-7.89%)
306.67M
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.08M
CRKNCrown Electrokinetics Corporation
$ 0.1073
(6.24%)
232.62M
OBLGOblong Inc
$ 0.21
(19.32%)
146.15M

PACB Discussion

View Posts
Timing101 Timing101 2 weeks ago
holding and new levels now being created. Strong Chart
👍️0
Monksdream Monksdream 1 month ago
PACB new 52 lo
👍️0
Monksdream Monksdream 2 months ago
PACB new 52 lo
👍️0
Monksdream Monksdream 10 months ago
PACB new 52 week high
👍️0
OptimusPrime555 OptimusPrime555 2 years ago
As I said earlier $4 coming!
👍️0
OptimusPrime555 OptimusPrime555 2 years ago
Back to $4
👍️0
@MomoPicks @MomoPicks 2 years ago
No bounce at all. Rough.
Should have just held my puts from the top.. was hoping I could get back in.
👍️0
OptimusPrime555 OptimusPrime555 2 years ago
Back to $4s soon!
👍️0
Glider549 Glider549 2 years ago
She doesn't have Tesla to ride on anymore.
👍️0
OptimusPrime555 OptimusPrime555 2 years ago
Where’s Cathy hiding these days???

ROFLMAO
👍️0
Porterhouse10 Porterhouse10 2 years ago
Hmmmm
👍️0
G3trich G3trich 3 years ago
https://finance.yahoo.com/news/pacific-biosciences-rady-children-institute-200500343.html

HiFi Sequencing will be used on a cohort of rare disease cases with the aim to identify numerous variants, both small and structural, that are not readily detectable by short-read sequencing

MENLO PARK, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Rady Children’s Institute for Genomic Medicine (RCIGM), a mission-driven, non-profit seeking to save lives and improve outcomes for patients, clinicians and families, shared today that they are collaborating on a study which aims to identify potential disease-causing genetic variants and increase the solve rates of rare diseases.

The study is focused on long-read whole genome sequencing of rare disease cases for which previous short-read whole genome and exome sequencing yielded no answers. The study, which is currently underway, was able to detect variants that were not identified by short-read sequencing (SRS); of these, an average of 37 were missense mutations in known disease genes.


“PacBio HiFi sequencing can identify numerous variants, both small and structural that are not readily detectable by SRS,” said Matthew Bainbridge, Principal Investigator, and Associate Director of Clinical Genomics at RCIGM. “We sequenced this cohort of patients to 10-30X depth of coverage using Pacific Biosciences HiFi long-read technology to assess whether there was an increase in the identification of these variants. We are very pleased by the preliminary results delivered in this collaboration with the team at PacBio.”

It is estimated that as many as 25 million Americans — approximately 1 in 13 people — are affected by a rare, and often undiagnosed condition. In rare disease studies, conventional techniques for whole-genome and whole-exome analysis based on SRS typically led to identification of a causal variant in less than 50% of cases. Utilizing PacBio’s Single Molecule, Real-Time (SMRT®) Sequencing technology to generate highly accurate long-reads, known as HiFi reads, clinical researchers have demonstrated that they can detect disease-causing structural and small variants missed by short-read sequencing platforms. This study is designed to evaluate the rate at which HiFi sequencing identifies overlooked causal variation.

“It is an honor to collaborate with the innovative pediatric translational researchers at RCIGM to bring HiFi Sequencing data to bear on some of their most difficult cases of rare pediatric disease, and hopefully give individuals and families answers regarding potential underlying genetic variants, which may ultimately provide healthcare providers with insights to end their diagnostic odysseys,” said Christian Henry, CEO and President at PacBio.

“We’ve been aware that there’s a subset of seriously ill babies and children who don’t receive a diagnosis with current sequencing methods, but based on their symptoms, we’re fairly certain that they have an underpinning genetic disease,” said Stephen Kingsmore, MD, DSc, President and CEO of Rady’s Children’s Institute for Genomic Medicine. “With this new technology, we are excited to see how many more of these children and families will receive additional insight regarding the identification of potential disease-causing genetic variants.”

About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit www.pacb.com and follow @PacBio.

About Rady Children’s Institute for Genomic Medicine
We are transforming pediatric critical care by advancing disease-specific healthcare for infants and children with rare disease. Discoveries at the Institute are enabling rapid diagnosis and targeted treatment of critically ill newborns and pediatric patients at Rady Children’s Hospital-San Diego and a growing network of more than 60 children’s hospitals nationwide. The vision is to expand delivery of this life-changing technology to enable the practice of Rapid Precision Medicine™ at children’s hospitals across the nation and the world. RCIGM is a non-profit, research institute of Rady Children’s Hospital and Health Center. Learn more at www.RadyGenomics.org. Follow us on Twitter and LinkedIn.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to the collaboration between PacBio and RCIGM, potential use of SMRT sequencing technology to identify, and increase the rate of identification of, potential disease-causing genetic variants in rare disease, the potential of HiFi data, the applications, insights, and attributes of SMRT sequencing technology, and the benefits of PacBio sequencing. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements contained in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Forms 8-K, 10-K, and 10-Q. The Company disclaims any obligation to update or revise any forward-looking statements.

Contacts

Investors:
Todd Friedman
+1 (650) 521-8450
ir@pacificbiosciences.com

Media:
Jen Carroll
+1 (858) 449-8082
pr@pacificbiosciences.com
👍️0
LetGoodTimesRoll LetGoodTimesRoll 3 years ago
Yes it has!!
👍️0
Timetravelerdos Timetravelerdos 3 years ago
I like both PACB and BNGO. The avg volume for PACB is 2.98 million vs BNGO which is 29.08 Million. Yes BNGO costs less but 975% is a HUGE difference in volume. ST 12,621 people watch PACB and 101,207 watch BNGO. 802% more people watching BNGO vs PACB. Buy both and Enjoy as they keep progressing.
Plus Cathie Wood likes PACB !
👍️0
Timetravelerdos Timetravelerdos 3 years ago
Outstanding earnings report !! Pacific Biosciences of California, Inc. Announces First Quarter 2021 Financial Results
9:47 am ET April 30, 2021 (Globe Newswire) Print
Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021.

Record first quarter revenue reflects a strong start to 2021

Revenue for the first quarter of 2021 was $29.0 million, representing an 86% increase compared with $15.6 million for the first quarter of 2020. The Company placed 41 Sequel II/IIe systems during the first quarter of 2021 compared to 11 Sequel II systems placed in the first quarter of 2020 and 35 Sequel II/IIe systems placed during the fourth quarter of 2020, bringing the total installed base of Sequel II/IIe systems to 244 as of March 31, 2021, compared with 125 as of March 31, 2020 and 203 as of December 31, 2020. Instrument revenue for the first quarter of 2021 was $14.9 million, compared with $4.0 million for the first quarter of 2020. Consumables revenue for the first quarter of 2021 was $10.4 million compared with $8.3 million for the first quarter of 2020. Service and other revenue for the first quarter of 2021 was $3.7 million compared with $3.3 million for the first quarter of 2020.

Gross profit for the first quarter of 2021 was $13.0 million, representing a 73% increase compared with $7.5 million for the first quarter of 2020. Gross margin for the first quarter of 2021 was 45%, compared to 48% for the first quarter of 2020.

Operating expenses totaled $46.7 million for the first quarter of 2021, compared to $40.2 million for the first quarter of 2020. Operating expenses for the first quarter of 2021 and first quarter of 2020 included non-cash stock-based compensation of $9.2 million and $3.5 million, respectively.

Net loss for the first quarter of 2021 was $87.4 million, compared to a net income of $1.3 million for the first quarter of 2020. The net loss for the first quarter of 2021 was largely driven by the repayment of $52 million of Continuation Advances to Illumina in the first quarter of 2021 as a result of the investment from SoftBank. First quarter 2020 included $34 million in other income from Continuation Advances from Illumina.

Basic and diluted net loss per share for the first quarter of 2021 was $0.45 per share compared to basic and diluted net income of $0.01 per share for the first quarter of 2020.

In February 2021, SB Northstar LP, a subsidiary of SoftBank Group Corp., made an investment of $900 million in convertible senior notes to support the Company's future growth initiatives. Cash, cash equivalents and investments, excluding short and long-term restricted cash, at March 31, 2021 totaled $1,160.3 million, compared to $318.8 million at December 31, 2020.
👍️0
Timetravelerdos Timetravelerdos 3 years ago
10 Best Pharma Stocks to Buy Now Pacific Biosciences ranks 8th on the list of 10 best pharma stocks to buy now. The company makes systems and technologies for gene sequencing. The company offers a single-molecule real-time sequencing (SMRT) platform based on properties of zero-mode waveguides. In February, the stock was upgraded by Piper Sandler to overweight from neutral with a price target of $52, up from $20. The firm cited Softbank’s $900 million investment in the company for the upgrade.

As of the end of the fourth quarter, 23 hedge funds in Insider Monkey’s database of 887 funds held stakes in PACB, compared to 25 funds in the third quarter. Cathie Wood's ARK Investment Management is the biggest stakeholder in the company, with 28.5 million shares, worth $739.4 million.

In the Q4 2020 Investor Letter, Baron Discovery Fund highlighted a few stocks and Pacific Biosciences Of California Inc. (NASDAQ:PACB) is one of them. Here is what Baron Discovery Fund said:

"Pacific Biosciences of California, Inc. offers a differentiated long-read DNA sequencing platform for genetic analysis. Shares performed exceedingly well in the quarter, up about 162%. We believe there is increasing excitement about the potential for its platform as it lowers sequencing costs and has the potential to move beyond its current commercial niche. The recently appointed CEO, Christian Henry, had previously served as CFO and Chief Commercial Officer at Illumina, and we think he is well qualified to commercially execute on Pacific Biosciences’ differentiated long-read platform.”

https://finance.yahoo.com/news/10-best-pharma-stocks-buy-144603194.html
👍️0
Timetravelerdos Timetravelerdos 3 years ago
Awesome News!!!! Biden admin will spend $1.6B to expand Covid-19 testing and sequencing !

CDC will use approximately $200 million to increase its capacity to sequence the genomes of virus samples from 7,000 samples per week to 25,000. Sequencing can reveal how variants of the virus — which may be more transmissible, more virulent or both — are spreading, and whether new variants are emerging.

The U.S. sequencing effort has lagged below the level needed to monitor how the coronavirus is changing, experts have said. At least three major variants first spotted overseas are now present in the United States, and there are reports of emerging homegrown virus strains.
“Genomic sequencing testing is how we will spot variants early before they spread,” Covid-19 coordinator Jeff Zients said.
👍️0
Planopenny Planopenny 3 years ago
I did pretty well, nothing to complain about. Not looking back. Gl to all here though
👍️0
Jack Tripper99 Jack Tripper99 3 years ago
Sold before earnings stupidly. Just loaded up again tho, their earnings, the merger and the recent sentiment is just too much. Go PACB
👍️0
Timetravelerdos Timetravelerdos 3 years ago
Good Call !!!!
• Pacific Biosciences of California (NASDAQ:PACB): Q4 GAAP EPS of $0.37 beats by $0.06.
• Revenue of $27.14M (-2.8% Y/Y) beats by $1.6M.
• Cash, equivalents and investments, excluding short-term restricted cash and long-term restricted cash, at Dec. 31, 2020 totaled $318.8M.

👍️0
alwaysthankfull alwaysthankfull 3 years ago
Sorry to see you go this one is a diamond in the rufffff $PacB
👍️0
Planopenny Planopenny 3 years ago
Been a good ride...im out! Weee
👍️0
Timetravelerdos Timetravelerdos 3 years ago
FABULOUS NEWS !!!!! Go PACB !!!!!
👍️0
Planopenny Planopenny 3 years ago
Slow claps
👍️0
Jack Tripper99 Jack Tripper99 3 years ago
Woo-hoo!!!
👍️0
Timetravelerdos Timetravelerdos 3 years ago
$900 MILLION INVESTMENT into PACB !!! GET into PACB ASAP

SoftBank Group Corp. plans to put $900 million into red-hot gene-sequencing company Pacific Biosciences of California Inc., as the Japanese technology conglomerate ramps up a new public-equity investing effort.
👍️0
JJ8 JJ8 3 years ago
timetravelerdos,

Did well with the first runup.

I may try to hold this time, at least for tripling or more.

One never knows. For this time it's almost doubled. Price/Volume momentum dynamic is interesting to follow.

I hope you have done well with PACB.

GLTY
👍️0
Timetravelerdos Timetravelerdos 3 years ago
You are doing very well in BNGO and almost the the $10 from the 17th that you wanted. BNGO is part of the ARKG fund. Cathie Wood knows her stuff as there ETFs are simply awesome. I am in long term with BNGO and enjoying the returns.
👍️0
G3trich G3trich 3 years ago
Simon-Barnett By Simon Barnett | @sbarnettARK
Analyst

During the J.P. Morgan Healthcare Conference last week, Invitae (NVTA), a leading medical genetics company, and Pacific Biosciences “PacBio” (PACB), a provider of long-read sequencing instruments, announced a collaboration to develop an ultra-high-throughput sequencing platform based on PacBio’s HiFi sequencing chemistry. This collaboration could increase the number of threats to companies focused on short-read sequencing.

Bolstered not only by results from this year’s PrecisionFDA Truth Challenge but also by improvements in HiFi accuracy via Google’s (GOOGL) DeepVariant as well as research community feedback, we think PacBio’s HiFi sequencing method provides the most complete and accurate view of the human genome.

To drive widespread adoption, PacBio likely needs to improve instrument throughput and variable cost. Collaborating with Invitae, we imagine PacBio can gain critical insights into its customers’ challenges, from automated sample prep to large-scale data processing. Invitae’s high sample volume could help PacBio’s long-read sequencing to capitalize on its Wright’s Law curve, as costs decline 28% for every cumulative doubling in the number of whole human genomes sequenced on long-read machines.

In our opinion, HiFi sequencing should help Invitae pull further away from its competition in the molecular diagnostics space, enabling the detection and evaluation of hard-to-sequence variants that could change patient management meaningfully. Unlike with short-read sequencing, HiFi-sequenced genomes should allow for the digital reassessment of patients’ DNA throughout their lifetimes, especially as researchers learn more about hard-to-sequence genes and the effects of structural variation within the human genome.

Ultimately, we believe the combination of talent, resources, know-how, and sample volume should allow both companies push long-read sequencing into routine medical practice faster than otherwise would be the case. By publishing data on clinical utility and diagnostic yields across disease types, they also should be able to demonstrate the system-wide value of HiFi sequencing over short-read whole genome sequencing.
👍️0
JJ8 JJ8 3 years ago
What do think of BNGO? They're also in genetic sequencing business- a biotech firm.

Its share price is making great moves currently. I almost tripled my investment just in 2 sessions and sold at $6.75

I bought again at $5.25 and, it looks like it may reach $10 and may be go over that level.
👍️0
Jack Tripper99 Jack Tripper99 3 years ago
I'm thinking of entering a relatively large position with this company, by end of the week. I agreed when Cathie Wood said that this industry could be in the future FAANG. Thoughts?
👍️0
G3trich G3trich 3 years ago
https://www.bio-itworld.com/news/2021/01/15/pacbio-year-of-expansion-whole-genome-clinical-goals
👍️0
Planopenny Planopenny 3 years ago
Slow claps
👍️0
Timetravelerdos Timetravelerdos 3 years ago
Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform!
GlobeNewswire
8:03 AM ET

Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio's highly accurate HiFi sequencing to expand Invitae's whole genome testing capabilities.

"Whole genome sequencing has the ability to significantly improve diagnosis for a wide range of diseases and guide healthcare throughout life. This collaboration is aimed at developing the technology to make it affordable and accessible to all patients who can benefit from in-depth, full genome information," said Sean George, co-founder and Chief Executive Officer of Invitae. "Our work with PacBio to date has demonstrated the increased diagnostic yield and clinical utility of using information from high-quality, long-read genomes to guide patient care. We believe this world-class sequencing technology combined with our clinical capabilities will uniquely position us to deliver those benefits cost effectively at scale. We look forward to working with the PacBio team to develop a new generation of innovative whole genome-based offerings."

Identifying the many underlying genetic influences on human health is becoming increasingly critical to overall clinical care and prognosis and whole genome sequencing offers the most comprehensive view of medically relevant variations. As whole genome sequencing continues to grow into a preferred m ethod for genetic testing, it is expected by the Global Alliance for Genomics and Health that by 2025 as many as sixty million genomes will be sequenced. With the development of a new sequencing platform, Invitae and PacBio aim to enable a new class of cost-effective assays that could be used to accelerate the accessibility of a more comprehensive whole genome sequencing approach in areas including carrier screening, immune system response, and other heritable diseases.

"Invitae is a leader in medical genetic testing and has driven innovation in this area for more than a decade. We are excited to join forces to develop and implement this new platform which is built on our shared vision that broad access to whole genome sequencing in the clinic has the power to improve diagnosis and access to pre cision therapies," said Christian Henry, President and Chief Executive Officer of Pacific Biosciences. "Building on the proven performance of our HiFi sequencing, we believe that this new system will ultimately enable us to deliver the most clinically relevant whole genome at substantially less than $1,000 which we believe is a critical price threshold needed to expand adoption in routine medical care."

PacBio HiFi sequencing combines the high accuracy of Sanger sequencing (>99.9%) with long reads up to 25 kb. Together, the length and accuracy of HiFi reads provide excellent detection of variants from single nucleotide changes to large structural variants, even in hard-to-sequence regions of the genome.

Through the collaboration, both companies will commit significant resources to support development of a production-scale sequencing platform designed with the capacity to process clinical whole genomes at scale. Those resources are expected to include talent, technology and collaborative oversight, and Invitae will also invest capital to support development throughout the multi-year effort.

https://finance.yahoo.com/news/pacific-biosciences-invitae-develop-ultra-130200103.html
👍️0
Jack Tripper99 Jack Tripper99 3 years ago
Congrats to holders, this will likely run even more next week.

Such an interesting company. Cathie Wood is right, this could be a world changing industry. Potential is unreal.
👍️0
G3trich G3trich 3 years ago
https://seekingalpha.com/news/3650074-softbank-takes-stake-in-pacific-biosciences-bloomberg?mail_subject=pacb-softbank-takes-stake-in-pacific-biosciences-bloomberg&utm_campaign=rta-stock-news&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha

Jan. 08, 2021 4:38 PM ETSoftBank Group Corp. (SFTBY)By: Vandana Singh, SA News Editor
SoftBank (OTCPK:SFTBY) has reportedly amassed a stake of roughly 6% in Pacific Biosciences of California (NASDAQ:PACB), Bloomberg reports.
The interest, currently worth over $350M, underscores the fast-expanding portfolio of public equity investments by the Japanese conglomerate's asset management business SB Northstar.
In November, the company announced a public offering of $87M priced at $14.25/share.
Last year, the company was blocked by U.S. antitrust enforcers from merging with Illumina in a $1.1B deal.
PACB shares rose as much as 12% on the news before trading was halted.
👍️0
AnotherInvestor AnotherInvestor 3 years ago
That helped my search. Thank you.

They reportedly took a 6% stake
👍️0
Planopenny Planopenny 3 years ago
Softbank investment
👍️0
AnotherInvestor AnotherInvestor 3 years ago
*pop*
I wonder what happened
👍️0
Planopenny Planopenny 3 years ago
Slow claps
👍️0
Timetravelerdos Timetravelerdos 3 years ago
Thank You ARK Investments for showing the way on PACB. Sure glad I didn't listen to the BNGO fan club. It is dropping over $2.30 today and was halted once. yikes. PACB is rock solid and ARK really likes the company. There you have it - PACB !
👍️0
G3trich G3trich 3 years ago
Great thread on PacBio’s longreads by Ark Invest’s genomics analyst, Simon Barnett:

Long-read #NGS obeys Wright's Law.

For every cumulative doubling in sequence data generated across its install base, @PacBio has been able to lower (consumables) costs by roughly 30%, as shown below.

What could this imply about the future of long-read #sequencing? pic.twitter.com/kl4ENUCWsP— Charles Campbell Roberts (@CCRobertsARK) November 18, 2020
👍️0
Planopenny Planopenny 3 years ago
Weee
👍️0
alwaysthankfull alwaysthankfull 3 years ago
PacBio’s Never Been Stronger: New CEO, Christian Henry, Shares His Vision
Christian Henry, CEO, PacBio
2020 show mp3

https://mendelspod.com/podcasts/pacbio%E2%80%99s-never-been-stronger-new-ceo-christian-henry-shares-his-vision/
👍️0
Timetravelerdos Timetravelerdos 3 years ago
ARKG is why I finally bought in Friday. They keep buying PACB so I follow the leader. ARKG is an amazing fund and PACB is the #3 held company percentage wise in the account. That is an incredible endorsement!
Gotta buy more next week !
👍️0
Planopenny Planopenny 3 years ago
Slow claps
👍️0
alwaysthankfull alwaysthankfull 4 years ago
pacb.com/evolve
https://programs.pacificbiosciences.com/evolve?utm_source=Social+Media&utm_campaign=2020-10-Sequel-IIe-Announcement
https://www.pacb.com/wp-content/uploads/Product-Brochure-Sequel-IIe-System-Sequencing-evolved.pdf
👍️0
alwaysthankfull alwaysthankfull 4 years ago
PACBIO virtual 2020 Global summit!
https://twitter.com/PacBio/status/1329464490971303938/photo/1
$PacB
👍️0
Porterhouse10 Porterhouse10 4 years ago
Dang
👍️0
Planopenny Planopenny 4 years ago
Weee lol
👍️0

Your Recent History

Delayed Upgrade Clock